Enlitic raises $15m in Series B

Artificial intelligence-enhanced medical diagnostics developer Enlitic said today that it closed a $15 million Series B round. Enlitic is designing a platform that uses AI to develop algorithms to identify and analyze suspicious findings in medical images. The company’s first product is designed to interpret chest x-rays to triage normal from abnormal scans, and to detect and characterize more than 40 abnormalities. The round was led by Marubeni and joined by Capital Health as well as several top Australian investors, the San Francisco-based company said. Enlitic added that it has been working with Marubeni since 2017 to develop for the Japanese market, and that Capital Health previously led its Series A financing round. The company said that 10% of funding in the round was set aside for individual radiologists and other physicians who either trained or used the company’s medical AI solutions. “Closing this round is a significant advancement to help Enlitic achieve its ambitious strategy to make meaningful clinical products for radiology and the associated healthcare markets. This will allow Enlitic to scale production towards achieving AI models that cover the entire body, which will offer a significant impact to daily clinical workflows,” chief medical officer Dr. Anthony Upton said in a prepared statement. Funding from the rounds is slated for use in supporting and enhancing the company’s artificial intelligence product portfolio to expand eng...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Imaging Enlitic Source Type: news